ArticleThe American journal of tropical medicine and hygiene2018
"It's Like a Phantom Disease": Patient Perspectives on Access to Treatment for Chagas Disease in the United States.
Article in The American journal of tropical medicine and hygiene, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Screening forEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2020Pooled it
- Small is big: growing impact of small molecule mass spectrometry in infectious disease drug development.mSphere · 2026Review
- (In)coherence between Chagas disease policy and the experiences of those affected in Mexico: The need for a transdisciplinary approach.PLoS neglected tropical diseases · 2025Article
- Mapping health behaviour related to Chagas diagnosis in a non-endemic country: Application of Andersen's Behavioural Model.PloS one · 2022Article
- mSphere of Influence: Forgotten Questions.mSphere · 2021Article
- Assessing the effectiveness of Chagas disease education for healthcare providers in the United States.BMC infectious diseases · 2020Article
- Article
- Access to Chagas disease treatment in the United States after the regulatory approval of benznidazole.PLoS neglected tropical diseases · 2020Article
- Chagas Disease in the New York City Metropolitan Area.Open forum infectious diseases · 2020Article
- Congenital Chagas Disease in the United States: The Effect of Commercially Priced Benznidazole on Costs and Benefits of Maternal Screening.The American journal of tropical medicine and hygiene · 2020Article
- Chagas Disease and Healthcare Rights in the Bolivian Immigrant Community of São Paulo, Brazil.Tropical medicine and infectious disease · 2020Article
- WHF IASC Roadmap on Chagas Disease.Global heart · 2020Review
- Awareness of Chagas disease and socioeconomic characteristics of Bolivian immigrants living in Sao Paulo, Brazil.Revista do Instituto de Medicina Tropical de Sao Paulo · 2020Article
- Chagas Disease in the United States: a Public Health Approach.Clinical microbiology reviews · 2019Review
- Proposed multidimensional framework for understanding Chagas disease healthcare barriers in the United States.PLoS neglected tropical diseases · 2019Review
- A four-step process for building sustainable access to diagnosis and treatment of Chagas disease.Revista panamericana de salud publica = Pan American journal of public health · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chagas disease (CD) affects > 6 million people globally, including > 300,000 in the United States. Although early detection and etiological treatment prevents chronic complications from CD, < 1% of U.S. cases have been diagnosed and treated. This study explores access to etiological treatment from the perspective of patients with CD. In semi-structured interviews with 50 Latin American-born patients of the Center of Excellence for Chagas Disease at the Olive View-UCLA Medical Center, we collected demographic information and asked patients about their experiences managing the disease and accessing treatment. Patients were highly marginalized, with 63.4% living below the U.S. poverty line, 60% lacking a high school education, and only 12% with private insurance coverage. The main barriers to accessing health care for CD were lack of providers, precarious insurance coverage, low provider awareness, transportation difficulties, and limited time off. Increasing access to diagnosis and treatment will not only require a dramatic increase in provider and public education, but also development of programs which are financially, linguistically, politically, and geographically accessible to patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.